Title: Pfizer (NYSE_PFE) Discontinues Danuglipron Development After Safety Review in Study
Date: 2025-04-14 17:23
URL: https://finance.yahoo.com/news/pfizer-nyse-pfe-discontinues-danuglipron-172306284.html?.tsrc=rss

Oops, something went wrong Tip: Try a valid symbol or a specific company name for relevant results Oops, something went wrong Dow slides 700 points, Nasdaq leads market rout as Powell warns of 'challenging' tariff impact The Nasdaq was down over 4% as a tech-led sell-off intensified in late-afternoon trading The major indexes sank to session lows as Fed Chair Powell warned of stagflationary impacts from President Trump's tariffs. Powell sees 'challenging scenario' for Fed if Trump tariffs stoke inflation and slow growth The Nasdaq fell over 2%, leading the way down as Nvidia found itself caught in the crossfire of the US-China trade war. The Treasury secretary told us he thinks America's biggest CEOs should stop worrying about the economy. Here's why. The chipmaker's stock took a hit after it revealed the Trump administration's surprise new controls on exports to China. Stocks resume slide as Nvidia weighs on tech Retail sales surged in March at the biggest rate in over two years, in what was the latest sign of the US economy's pre-tariff strength. Why your water bill is an inflation problem that isn't budging Stock market today: Dow, S&P 500, Nasdaq futures fall as Nvidia reveals costly limits on China exports The Treasury secretary told Yahoo Finance that the next 90 days should provide 'substantial clarity' on tariffs Treasury Secretary Scott Bessent tells Yahoo Finance that the US has a 'big toolkit' to deal with bond market volatility Stocks drift lower as tariff chaos pauses for a day The chip giant committed to building AI infrastructure in the US, and Trump says he's going to help make it happen. The fallout from Trump's tariff whiplash hasn't yet pushed investors to shy away from an old habit Stocks edge higher after back-to-back rallies with Trump's latest tariff moves in focus BofA's Moynihan says 'we potentially face a changing economy' after highest-ever equities trading haul The trade war uncovers new economies of scale Trump is wrecking his own economic agenda Higher clothing costs from tariffs are coming soon — but not immediately, experts say Why Tesla, GM, and Rivian will be hurt most by China's critical minerals export ban Trump says he's 'looking at something' to help car companies with tariffs Stocks rally for second straight day, while Apple jumps on tech tariff reprieve The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found Stocks surge as Apple leads way higher after tech's tariff reprieve Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows Corporate earnings take center stage amid tariff turmoil: What to know this week Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg) Tax day 2025 is coming up. Here’s what to know to file by the deadline. Commentary: Put the P/E ratio in timeout for now Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing Apple was on brink of crisis before tariff concession from Trump (Bloomberg) Corporate earnings take center stage amid tariff turmoil: What to know this week The best (and worst) time of year to buy a house The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg) How to invest in gold in 4 steps Changing jobs can disrupt saving for retirement. Here's how to stay on track. Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg) Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of The tariff uncertainty isn't getting any better in markets: Chart of the Week 'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation Gold notches best week since 2020 amid 'shaken' investor confidence in US The bond market just had one of its most volatile and unusual weeks in recent memory Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023 Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains. The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market. Unlock stock picks and a broker-level newsfeed that powers Wall Street. Pfizer recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety concerns in clinical studies. Despite achieving key pharmacokinetic goals, the discovery of a potential drug-induced liver injury prompted Pfizer to reassess its strategy. This decision adds weight to the company's stock performance, contrasting with broader market trends, where major indexes experienced upward movement amidst tariff-related developments and positive gains in tech sectors. Pfizer's decision highlights the importance of rigorous safety evaluations in pharmaceutical developments. We've discovered 3 warning signs for Pfizer (2 are significant!) that you should be aware of before investing here. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The cessation of Danuglipron’s development could significantly influence Pfizer's revenue and earnings forecasts moving forward. By prioritizing rigorous safety measures, Pfizer may face setbacks in accelerating R&D productivity and the associated revenue streams. This shift may lead to a more conservative approach in pipeline-driven growth expectations and could delay anticipated financial impacts from new products, potentially further pressuring revenue forecasts already impacted by legislative changes. The development halt aligns with observed market volatility around Pfizer shares, shedding light on investor concerns regarding the company's future earning capabilities amidst evolving challenges in the pharmaceutical sector. Over the past year, Pfizer's total return, including dividends, was a 10.14% decline, signaling underperformance relative to both the broader market and the US Pharmaceuticals industry, which experienced negative returns of 8.6%. During this period, the company's earnings showed considerable growth from a very low base, yet they have not matched market expectations overall. Notably, analysts have set a fair value price target of US$26.02, suggesting upside potential compared to the current share price of US$22.49. However, this assumes improvements in profit margins and financial performance that are not without risk given current operational challenges and headwinds from pricing reforms in Medicare. Understand Pfizer's track record by examining our performance history report.  This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com A net gain on a home sale of $680k potentially could lead to having to pay capital gains taxes. But in many cases, you won't have to pay taxes on the full amount of the gain. And you may be able to shield all of it. This is due to an exclusion that protects from […] The post I’m Selling My House and Netting $680k. Do I Have to Worry About Capital Gains Taxes? appeared first on SmartReads by SmartAsset. We recently published a list of Jim Cramer Sounds the Alarm on China Rhetoric and Dollar Panic Then Analyzes 11 Key Stocks. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other key stocks that Jim Cramer analyzes. In his latest appearance on CNBC’s Squawk on the […] Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues. CVS Health and UnitedHealth are two of the top companies leading the S&P 500 chart YTD. But which is the better investment now? Let's take a closer look. We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […] What does PepsiCo do?  The company in question is PepsiCo (NASDAQ: PEP).  Although largely known for its namesake beverages, it operates in the beverage, snack (Frito-Lay), and packaged food (Quaker Oats) categories. (Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade When investing in crypto, it helps to look at the top performers to get a sense of what’s going on in the market. Here are our top picks for the best online brokers for bonds. Here’s how inheriting an annuity works and what to do with it. Tip: Try a valid symbol or a specific company name for relevant results Sign in to access your portfolio 


Try again.
